The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Expanding colorectal cancer screening reach via stool-based testing
Theodore R. Levin, MD, Kaiser Permanente, Oakland, CA emphasizes the importance of considering the accessibility and reach of stool-based testing in colorectal cancer screening decisions. The ability to screen more people with this method should be a significant factor in policy and practice. The implementation of a stool-based option can increase screening rates, leading to better outcomes in terms of cancer and advanced polyp detection, removal, and ultimately cancer prevention. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
